Effects of dronedarone started rapidly after amiodarone discontinuation

Clinical Cardiology

Volumn 36, Issue 2, 2013, Pages 88-95

  Immordino, Laura ^a   Connolly, Stuart ^b   Crijns, Harry ^c   Roy, Denis ^d   Capucci, Alessandro ^e   Radzik, David ^f   Aliot, Etienne ^g   Hohnloser, Stefan ^h   Kowey, Peter ^a  

^a LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b MCMASTER UNIVERSITY   (Canada)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d MONTREAL HEART INSTITUTE   (Canada)

^e UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^f SANOFI   (France)

^g UNIVERSITY HOSPITAL OF NANCY   (France)

^h GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; DRONEDARONE; PLACEBO;

ADULT; AGED; ARTICLE; BRADYCARDIA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; FEMALE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART FAILURE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RETROSPECTIVE STUDY; TREATMENT DURATION;

AGED; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; BRADYCARDIA; DRUG SUBSTITUTION; FEMALE; HALF-LIFE; HEART FAILURE; HOSPITALIZATION; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PATIENT SELECTION; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84873738276     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22090     Document Type: Article

References (18)

1. Olshansky B, Rosenfeld LE, Warner AL, et al. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol. 2004; 43: 1201-1208. (Pubitemid 38452597)
2. Singh BN, Singh SN, Reda DJ, et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med. 2005; 352: 1861-1872.
3. Wann LS, Curtis AB, January CT, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011; 123: 104-123.
4. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Guidelines for the management of atrial fibrillation. Eur Heart J. 2010; 31: 2369-2429.
5. Rätz Bravo AE, Drewe J, Schlienger RG, et al. Hepatotoxicity during rapid intravenous loading with amiodarone: description of three cases and review of the literature. Crit Care Med. 2005; 33: 128-134; discussion 245-246. (Pubitemid 40116547)
6. Sun W, Sarma JS, Singh BN., Electrophysiological effects of dronedarone (SR33589), a noniodinated benzofuran derivative, in the rabbit heart: comparison with amiodarone. Circulation. 1999; 100: 2276-2281.
7. Touboul P, Brugada J, Capucci A, et al. Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J. 2003; 24: 1481-1487. (Pubitemid 37010577)
8. Singh BN, Connolly SJ, Crijns HJ, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007; 357: 987-999. (Pubitemid 47367078)
9. Hohnloser SH, Crijns HJ, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation [published corrections appear in N Engl J Med. 2009;360:2487 and 2011;364:1481]. N Engl J Med. 2009; 360: 668-678.
10. Køber L, Torp-Pedersen C, McMurray JJ, et al. Dronedarone Study Group. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008; 358: 2678-2687. (Pubitemid 351860860)
11. Connolly SJ, Crijns HJ, Torp-Pedersen C, et al. ATHENA Investigators. Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter. Circulation. 2009; 120: 1174-1180.
12. Multaq [prescribing information]. Bridgewater, NJ: sanofi-aventis; 2012.
13. Multaq [summary of product characteristics]. Paris, France: Sanofi; 2012.
14. AJ Camm, GY Lip, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation-developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012; 14: 1385-1413.
15. Le Heuzey JY, De Ferrari GM, Radzik D, et al. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol. 2010: 21: 597-605.
16. Pollak PT, Sharma AD, Carruthers SG., Creatinine elevation in patients receiving amiodarone correlates with serum amiodarone concentration. Br J Clin Pharmacol. 1993; 36: 125-127. (Pubitemid 23234604)
17. Batcher EL, Tang XC, Singh BN, et al. Thyroid function abnormalities during amiodarone therapy for persistent atrial fibrillation. Am J Med. 2007; 120: 880-885. (Pubitemid 47451295)
18. Cohen-Lehman J, Dahl P, Danzi S, et al. Effects of amiodarone therapy on thyroid function. Nat Rev Endocrinol. 2010; 6: 34-41.